Onsdag 18 November | 10:32:57 Europe / Stockholm
Est. tid*
2027-05-19 N/A Årsstämma
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-18 08:30 Kvartalsrapport 2026-Q3
2026-08-19 - Kvartalsrapport 2026-Q2
2026-05-21 - X-dag ordinarie utdelning REDS 0.00 SEK
2026-05-20 - Årsstämma
2026-05-20 - Kvartalsrapport 2026-Q1
2026-02-19 - Bokslutskommuniké 2025
2025-11-19 - Kvartalsrapport 2025-Q3
2025-08-20 - Kvartalsrapport 2025-Q2
2025-05-28 - Årsstämma
2025-05-28 - Kvartalsrapport 2025-Q1
2025-05-15 - X-dag ordinarie utdelning REDS 0.00 SEK
2025-04-24 - Extra Bolagsstämma 2025
2025-02-26 - Bokslutskommuniké 2024
2024-11-26 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-10 - X-dag ordinarie utdelning REDS 0.00 SEK
2024-05-08 - Årsstämma
2024-05-08 - Kvartalsrapport 2024-Q1
2024-02-27 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-10 - X-dag ordinarie utdelning REDS 0.00 SEK
2023-05-09 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-27 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-29 - Kvartalsrapport 2022-Q2
2022-05-03 - X-dag ordinarie utdelning REDS 0.00 SEK
2022-05-02 - Årsstämma
2022-05-02 - Kvartalsrapport 2022-Q1
2022-02-28 - Bokslutskommuniké 2021
2021-11-09 - Kvartalsrapport 2021-Q3
2021-08-24 - Kvartalsrapport 2021-Q2
2021-05-12 - Årsstämma
2021-05-05 - X-dag ordinarie utdelning REDS 0.00 SEK
2021-05-03 - Kvartalsrapport 2021-Q1
2021-04-19 - Extra Bolagsstämma 2021
2021-02-28 - Bokslutskommuniké 2020
2020-12-18 - Extra Bolagsstämma 2020
2020-11-09 - Kvartalsrapport 2020-Q3
2020-08-24 - Kvartalsrapport 2020-Q2
2020-06-23 - X-dag ordinarie utdelning REDS 0.00 SEK
2020-06-22 - Årsstämma
2020-05-04 - Kvartalsrapport 2020-Q1
2020-02-25 - Bokslutskommuniké 2019
2019-11-18 - Kvartalsrapport 2019-Q3
2019-08-26 - Kvartalsrapport 2019-Q2
2019-05-07 - X-dag ordinarie utdelning REDS 0.00 SEK
2019-05-06 - Årsstämma
2019-05-06 - Kvartalsrapport 2019-Q1
2019-02-26 - Bokslutskommuniké 2018
2018-08-27 - Kvartalsrapport 2018-Q2
2018-05-08 - X-dag ordinarie utdelning REDS 0.00 SEK
2018-05-07 - Årsstämma
2018-02-27 - Bokslutskommuniké 2017
2017-09-25 - Extra Bolagsstämma 2017
2017-08-28 - Kvartalsrapport 2017-Q2
2017-04-06 - X-dag ordinarie utdelning REDS 0.00 SEK
2017-04-05 - Årsstämma
2017-02-22 - Bokslutskommuniké 2016
2016-10-26 - Kvartalsrapport 2016-Q3
2016-08-25 - Kvartalsrapport 2016-Q2
2016-05-09 - Årsstämma
2016-05-09 - Kvartalsrapport 2016-Q1
2016-02-23 - X-dag ordinarie utdelning REDS 0.00 SEK
2016-02-22 - Bokslutskommuniké 2015
2015-11-27 - Kvartalsrapport 2015-Q3
LandSverige
ListaSpotlight
SektorHälsovård
IndustriMedicinteknik
Redsense Medical är ett svenskt medicinteknikbolag som utvecklar och säljer system för övervakning av blodläckage vid hemodialysbehandling. Bolagets produkter bygger på fiberoptisk sensorteknik som upptäcker blodläckage och aktiverar ett larm. Sortimentet omfattar sensorer, larmenheter och tillhörande utrustning för användning inom sjukvården och vid dialys i hemmet. Verksamheten bedrivs främst i Europa och USA och har sitt huvudkontor i Halmstad.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Interim Report Q3 - January - September, 2026 Redsense Medical AB (publ.)

2026-11-18 08:30:00

July -  September 2026

  • Net sales amounted to kSEK 7,630 (6,935).
  • Operating result, EBIT amounted to kSEK 1,268 (-428).
    • EBIT excl. exchange rate differences kSEK 1,046 (-226).
  • Result after tax amounted to kSEK 1,329 (-345).
  • Earnings per share were SEK 0.08 (-0.02).
  • Exchange rate differences kSEK 222 (-202).

(Other operating income/loss)

Message from the CEO

Consistency providing a stronger foundation for growth

The third quarter marks our third consecutive quarter with a positive operating result and year-on-year revenue growth. Net sales increased to kSEK 7,630 (6,935), with an operating result of kSEK 1,268 (-428). For the first nine months, net sales reached kSEK 21,121 (17,988) and the operating result improved to kSEK 2,722 (-5,414). Together with a cash position exceeding SEK 12 million at the end of September, this demonstrates the more stable operational and financial foundation we have worked to establish.

Underlying demand also continues to develop positively. In the U.S., alarm sales from our distribution partners to end customers increased by approximately 2 percent, while sensor patch sales grew by 12 percent compared with the same quarter last year. This continues the trend of increasing disposable usage alongside relatively stable alarm sales, indicating that our systems are being used more actively.

We continue to work closely with our largest U.S. providers, where discussions around broader implementation and increased usage are progressing. The revised pricing structure, together with our educational support and closer engagement with clinical and procurement teams, remains central to addressing barriers to wider adoption.

Broadening our commercial reach

During the quarter, we participated in several industry meetings and conferences in the U.S. and Europe, with an increased emphasis on nursing-focused events. As more of these meetings have returned following the pandemic, we have been able to reconnect with an audience that has historically been particularly relevant for Redsense. Nurses are the primary users of our technology, and these meetings provide valuable opportunities for product demonstrations, practical feedback and building relationships with clinical decision-makers.

We also returned to the European renal nursing conference, EDTNA, where we presented the Redsense Clamp alongside our established alarm system. For healthcare professionals already familiar with Redsense, the expanded offering generated renewed interest and valuable discussions. While these interactions do not necessarily translate directly into sales, they help maintain awareness and support our ongoing commercial work. Our distribution partners also represented Redsense at national industry meetings in the UK and Canada, while we continued our engagement with providers at the German national nephrology meeting.

Commercial progress for the Clamp continues, although decision processes at larger organisations are taking longer than anticipated. We have recorded smaller sales and received positive feedback from clinical evaluations in both the UK and Germany. Discussions regarding pricing and wider implementation remain ongoing with several larger providers. Our priority is to convert these opportunities into more substantial and repeatable business, while maintaining a disciplined approach to our commercial resources.

Our digital training portal is also gaining users, with more healthcare professionals accessing the platform and providing encouraging initial feedback. We continue to develop the solution to support consistent implementation and make training more accessible across clinics and provider organisations.

Regulatory progress and market opportunities 

For the Redsense Clamp in the U.S., we have submitted a request for a follow-up FDA pre-submission meeting. More than three years have passed since our previous dialogue, during which both our product development and regulatory expectations have evolved. We believe renewed engagement is the most efficient way to review our progress, clarify current requirements and evaluate the most appropriate regulatory pathway before proceeding with a formal submission. We will communicate further developments as the process progresses.

Following the quarter, the U.S. Department of Health and Human Services published a new national kidney care plan, reinforcing the focus on home dialysis, patient safety and innovation in kidney care. We view this as a positive development for the market in which Redsense is already established, particularly in home and nocturnal dialysis. We are exploring whether the renewed policy focus may also create opportunities for further engagement around broader adoption, while recognising that reimbursement pathways remain challenging.

Outlook

The first nine months of 2026 demonstrate that the improvements implemented during 2025 are translating into more consistent performance. With three consecutive positive quarters, growing disposable usage and a stronger financial position, we have established a solid foundation from which to develop the business further.

Our focus remains on increasing usage within our existing U.S. customer base, expanding into additional clinics and patient groups, and converting ongoing Clamp opportunities in Europe into larger commercial agreements. We remain encouraged by the interest and feedback from customers, while recognising that implementation decisions within larger healthcare organisations require time.

We will continue to balance commercial ambition with financial discipline, building a business capable of supporting sustainable growth and reaching more patients with improved safety in dialysis care. I would also like to thank the entire Redsense team for their dedication and hard work. The progress we are seeing is the result of a collective effort, and I am proud of what we are achieving together.

Sebastien Bollue
CEO of Redsense Medical

This information is information that Redsense Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Market Act. The information was submitted for publication, through the agency of the contact person specified below, on November 18, 2026, at 08:30 CET.